ARQT - Arcutis Biotherapeutics

-

$undefined

N/A

(N/A)

Arcutis Biotherapeutics NasdaqGS:ARQT Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Location: 3027 Townsgate Road, Westlake Village, CA, 91361, United States | Website: https://www.arcutis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.542B

Cash

198.1M

Avg Qtr Burn

-27.73M

Short % of Float

18.67%

Insider Ownership

1.95%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZORYVE® (Roflumilast foam 0.3%) Details
Skin disease/disorder, Seborrheic dermatitis

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

ZORYVE® (ARQ-151) topical roflumilast cream Details
Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision

ARQ-255 topical ivarmacitinib Details
Skin disease/disorder, Alopecia areata

Phase 1b

Data readout

ARQ-234 Details
Skin disease/disorder, Atopic dermatitis

IND

Submission

Failed

Discontinued

ARQ-252 (JAK1i) Details
Skin disease/disorder, Eczema

Failed

Discontinued